[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"residual-kidney-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:residual-kidney-function":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100494256","phase-3-mechanisms-and-safety-of-sglt2-inhibition-in-peritoneal-dialysis-100494256",false,"NCT05715814","meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis","A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function","CANARY","Inclusion Criteria:\n\n* Signed and dated written informed consent.\n* Patients aged ≥18 years on PD with RKF defined as at least 250 cc of urine output per day (assessed via 24-hour urine collection) and a minimum measured GFR of 2 ml\u002Fmin\u002F1.73m2, as measured at least once in the last 3 months.\n* Stable PD prescription, as determined by investigators.\n* Stable dose of RAAS blockade if on a medication within this class for the last 30 days.\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* Recent (in the 30 days prior to screening) acute coronary syndrome or cerebrovascular event.\n* PD peritonitis within 30 days of screening.\n* History of organ transplant, including pancreas, pancreatic islet cells or kidney transplant.\n* Planned surgery\u002Fprocedures or radiologic investigations requiring contrast during the trial.\n* Pregnant, planning to become pregnant, or nursing an infant during the study period\n* History of any DKA event\n* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, hemolytic anemia) at screening.\n* Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.\n* Alcohol or drug abuse within the 3 months prior to screening that would interfere with trial participation based on Investigator's judgement.\n* Use of SGLT2 inhibitor within 30 days prior to screening.\n* Intake of an investigational drug in another trial within 30 days prior to screening.\n* Patient not able to understand and comply with study requirements, based on Investigator's judgment.\n* Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g. immunocompromised patients, active malignancy, patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections, uncontrolled hypertension, cardiorenal and\u002For hepatorenal syndrome, severe hepatic impairments etc.).","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).",[27,28,29,30,31],"Peritoneal Dialysis Complication","End Stage Kidney Disease","Sodium-glucose Co-transporter-2 Inhibitors","Kidney Dysfunction","Residual Kidney Function","RECRUITING","2026-04-30",{"date":35,"type":36},"2026-05-01","ACTUAL",{"date":38,"type":36},"2024-09-01",{"date":40,"type":21},"2027-12-01",{"name":42,"class":43},"University Health Network, Toronto","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100553206","phase-2-empagliflozin-on-residual-kidney-function-in-incident-peritoneal-dialysis-patients-100553206","NCT06483074","Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients","Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients: a Pilot Randomized Controlled Trial","EMPIRIC-PD","Inclusion Criteria:\n\n1. Incident PD patients within 90 days of Tenckhoff catheter insertion\n2. Age 18-75 years old\n3. Patient with or without history of Type 2 diabetes\n4. Residual GFR (defined as the average of 24-hour urinary urea and creatinine clearances) \\> 2ml\u002Fmin\u002F1.73m2 AND urine volume \\> 400ml per day\n5. Patients who are willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Patients with history of hemodialysis (≥ 3 months) or renal transplant\n2. Life expectancy \\\u003C6 months\n3. Prior use of any type of SGLT2 inhibitors within 1 month before screening visit\n4. Poorly controlled diabetes with HBA1c \\>11%\n5. Type 1 diabetes\n6. History of any active malignancy within 5 years (except curatively resected basal cell or squamous cell skin cancers)\n7. Peritonitis within 4 weeks\n8. Ketoacidosis within 5 years\n9. Known hypersensitivity to empagliflozin or other SGLT2 inhibitors\n10. Any active acute or chronic physical or mental conditions that, in the opinion of the investigator, might interfere with the compliance of participants to or the performance of this study\n11. Participation in any clinical trial or use of any investigational medicinal product 1 month before screening visit","75 Years",{"count":55,"type":21},48,[57],"PHASE2","Empagliflozin, a new class of diabetes medication, has demonstrated a reduction in renal function decline among patients with chronic kidney disease, regardless of their diabetes status. However, all previous studies excluded dialysis patients. Patients starting dialysis may still produce a certain amount of urine. Importantly, patients with better preserved residual kidney function tend to have better control of blood pressure and volume status, improved nutrition status, higher quality of life and reduced mortality rate.\n\nThe purpose of this study is to learn about the safety of empagliflozin in patients on peritoneal dialysis, in preparation for a future large clinical trial. Participants who newly initiate peritoneal dialysis will be randomly allocated to either empagliflozin on top of standard of care, or standard of care alone. Over a follow-up period of six months, the investigators will collect information on urine volume, blood pressure and glucose control. Safety, tolerability and drug compliance of empagliflozin will also be evaluated. If empagliflozin is found to be safe and well tolerated in patients on peritoneal dialysis, further large-scale randomized controlled trial may be conducted to evaluate its impact on residual kidney function and other relevant clinical outcomes.",[60,27,61,31],"End Stage Renal Disease on Dialysis","Sodium-glucose Cotransporter-2 Inhibitor","2025-08-02",{"date":64,"type":36},"2025-08-06",{"date":66,"type":36},"2024-07-29",{"date":68,"type":21},"2026-10-31",{"name":70,"class":43},"Chinese University of Hong Kong",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100525256","incremental-pd-with-single-icodextrin-exchange-100525256","NCT06119373","Incremental PD With Single Icodextrin Exchange","Initiation of Incremental Dialysis With Single Daily Icodextrin Exchange: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. male or female patients aged 18 to 75 years;\n2. patients with chronic kidney disease stage 5 who are to start PD;\n3. eGFR ≥ 5 ml\u002Fmin;\n4. urine output ≥ 800 ml\u002Fd.\n\nExclusion Criteria:\n\n1. documented anaphylaxis with icodextrin or glucose-based dialysate;\n2. concomitant severe chronic diseases such as malignancy, hepatitis, severe cardiac diseases, etc.;\n3. ongoing severe infection;\n4. planned or ongoing pregnancy or lactation;\n5. currently enrolled in other clinical studies;\n6. patients who have a life expectancy of \\\u003C12 months;\n7. refusal to give a written consent.",{"count":79,"type":21},72,[81],"NA","Objectives: To investigate the efficacy and safety of single daily icodextrin exchange for initiation of incremental peritoneal dialysis (PD).\n\nSubjects: Seventy-two incident PD patients.\n\nMethods: A single-center randomized controlled trial.\n\nPrimary outcome: Change in residual kidney function in 48 weeks after recruitment.",[27,31,84,85],"Survival","Health-related Quality of Life","NOT_YET_RECRUITING","2023-11-05",{"date":89,"type":36},"2023-11-08",{"date":91,"type":21},"2023-12-01",{"date":93,"type":21},"2026-11-30",{"name":95,"class":43},"RenJi Hospital"]